Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Behavioural Brain Research

• Publication date

  2010-02-11

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.bbr.2009.09.048PMID 19822174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neto1 Is a Novel CUB-Domain NMDA Receptor–Interacting Protein Required for Synaptic Plasticity and Learning

  2009cited by this paper
• D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.

  2009cited by this paper
• Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia—sub-chronic and early postnatal PCP treatment in attentional set-shifting

  2009cited by this paper
• Positive AMPA Receptor Modulation Rapidly Stimulates BDNF Release and Increases Dendritic mRNA Translation

  2009cited by this paper
• Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

  2008cited by this paper
• Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat—a back translational study

  2008cited by this paper
• A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats.

  2008cited by this paper
• Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat

  2008cited by this paper
• Differential regulation of the NMDA receptor by acute and sub‐chronic phencyclidine administration in the developing rat

  2008cited by this paper
• A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia

  2008cited by this paper
• Processing spatial-temporal information in recent-onset schizophrenia: the study of short-term memory and its susceptibility to distraction.

  2007cited by this paper
• Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.

  2007cited by this paper
• Influence of gender on working and spatial memory in the novel object recognition task in the rat.

  2007cited by this paper
• Brain-Derived Neurotrophic Factor Expression and Respiratory Function Improve after Ampakine Treatment in a Mouse Model of Rett Syndrome

  2007cited by this paper
• P.1.c.029 Brain-derived neurotrophic factor downregulation in rat brain following sub-chronic phencyclidine administration

  2007cited by this paper
• Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats.

  2007cited by this paper
• The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm.

  2006cited by this paper
• Glutamate-based therapeutic approaches: ampakines.

  2006cited by this paper
• Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat

  2006cited by this paper
• Long-term potentiation and cognitive drug discovery.

  2005cited by this paper
• Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

  2004cited by this paper
• Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus.

  2004cited by this paper
• Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

  2004cited by this paper
• Chronic Elevation of Brain-Derived Neurotrophic Factor by Ampakines

  2003cited by this paper
• AMPA receptor trafficking and synaptic plasticity.

  2002cited by this paper
• A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia.

  2002cited by this paper
• Benzamide-Type AMPA Receptor Modulators Form Two Subfamilies with Distinct Modes of Action

  2002cited by this paper
• Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins.

  2002cited by this paper
• Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter

  2001cited by this paper
• A Placebo-Controlled Pilot Study of the Ampakine CX516 Added to Clozapine in Schizophrenia

  2001cited by this paper
• Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546.

  2001cited by this paper
• Positive Modulation of AMPA Receptors Increases Neurotrophin Expression by Hippocampal and Cortical Neurons

  2000cited by this paper
• Synergistic interactions between ampakines and antipsychotic drugs.

  1999cited by this paper
• The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia

  1999cited by this paper
• Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance

  1998cited by this paper
• The waveform of synaptic transmission at hippocampal synapses is not determined by AMPA receptor desensitization.

  1998cited by this paper
• Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans.

  1997cited by this paper
• Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics.

  1997cited by this paper
• AMPA Receptor Facilitation Accelerates Fear Learning without Altering the Level of Conditioned Fear Acquired

  1997cited by this paper
• Immunoautoradiographic evidence for a loss of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia

  1997cited by this paper
• Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia.

  1997cited by this paper
• Enhancement by an ampakine of memory encoding in humans.

  1997cited by this paper
• Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics

  1996cited by this paper
• Facilitation of olfactory learning by a modulator of AMPA receptors

  1995cited by this paper
• A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning‐dependent task

  1993cited by this paper
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro.

  1988cited by this paper
• The long and the short of long–term memory—a molecular framework

  1986cited by this paper
• Protein synthesis and memory: a review.

  1984cited by this paper
• Long‐lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path

  1973cited by this paper
• Study of a new schizophrenomimetic drug; sernyl.

  1959cited by this paper

• Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics

  2022cites this paper
• Beyond NMDA Receptors: Homeostasis at the Glutamate Tripartite Synapse and Its Contributions to Cognitive Dysfunction in Schizophrenia

  2022cites this paper
• The role of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type receptor modulators in object recognition memory reconsolidation

  2022cites this paper
• AMPAkines potentiate the corticostriatal pathway to reduce acute and chronic pain

  2021cites this paper
• Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: a long and winding road.

  2021cites this paper
• AMPA receptors mediate the pro-cognitive effects of electrical and optogenetic stimulation of the medial prefrontal cortex in antidepressant non-responsive Wistar–Kyoto rats

  2020cites this paper
• Ivermectin Protects against Monosodium Glutamate-Induced Excitotoxicity in the Rat

  2019influential citation
• Investigation into effects of chronic treatment with antipsychotics using a combination of behavioural and electrophysiological techniques

  2019cites this paper
• S 47445 counteracts the behavioral manifestations and hippocampal neuroplasticity changes in bulbectomized mice.

  2019cites this paper
• The reduction in glutamate release is predictive of cognitive and emotional alterations that are corrected by the positive modulator of AMPA receptors S 47445 in perinatal stressed rats

  2018cites this paper
• AMPAkines and morphine provide complementary analgesia.

  2017cites this paper
• Potentiation of excitatory synaptic transmission ameliorates aggression in mice with Stxbp1 haploinsufficiency

  2017cites this paper
• Pharmacological characterization of N‐[(2S)‐5‐(6‐fluoro‐3‐pyridinyl)‐2, 3‐dihydro‐1H‐inden‐2‐yl]‐2‐propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator

  2017cites this paper
• Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research

  2017cites this paper
• Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders.

  2016cites this paper
• Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.

  2016cites this paper
• Optogenetic Stimulation of Prefrontal Glutamatergic Neurons Enhances Recognition Memory

  2016influential citation
• Activation of Corticostriatal Circuitry Relieves Chronic Neuropathic Pain

  2015cites this paper
• Investigating the long-term effect of subchronic phencyclidine-treatment on novel object recognition and the association between the gut microbiota and behavior in the animal model of schizophrenia.

  2015cites this paper
• The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia

  2015cites this paper
• Molecular Mechanisms of Drug-Induced Cognitive Enhancement

  2015cites this paper
• Effects of green tea and physical exercise on memory impairments associated with aging.

  2014cites this paper
• In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia

  2014cites this paper
• The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia

  2014cites this paper
• α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazoleproprionic acid receptor activation protects against phencyclidine‐induced caspase‐3 activity by activating voltage‐gated calcium channels

  2014cites this paper
• Sigma 1 receptor activation regulates brain-derived neurotrophic factor through NR2A-CaMKIV-TORC1 pathway to rescue the impairment of learning and memory induced by brain ischaemia/reperfusion

  2014cites this paper
• The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.

  2014cites this paper
• Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions.

  2014cites this paper
• Xanthoceraside attenuates tau hyperphosphorylation and cognitive deficits in intracerebroventricular-streptozotocin injected rats

  2013cites this paper
• Structural analysis of the positive AMPA receptor modulators CX516 and Me-CX516 in complex with the GluA2 ligand-binding domain.

  2013cites this paper
• Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models.

  2012cites this paper
• The AMPA receptor potentiator Org 26576 modulates stress-induced transcription of BDNF isoforms in rat hippocampus.

  2012cites this paper
• NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.

  2012cites this paper
• AMPA receptor positive modulators

  2012cites this paper
• Translational PK–PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576

  2011cites this paper
• Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia

  2011cites this paper
• Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission

  2011cites this paper
• Effects of the putative cognitive-enhancing ampakine, CX717, on attention and object recognition memory.

  2011cites this paper
• Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models

  2011cites this paper
• Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats

  2011cites this paper
• A prospective study of cognitive deficits in first episode psychosis, and the response thereof to treatment with Flupenthixol Decanoate

  2011cites this paper
• Pharmacological Enhancement of Memory and Executive Functioning in Laboratory Animals

  2011cites this paper
• Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.

  2011cites this paper
• 12. Animal Models of Prenatal Protein Malnutrition Relevant for Schizophrenia

  2011cites this paper
• Translational Aspects of the Novel Object Recognition Task in Rats Abstinent Following Sub-Chronic Treatment with Phencyclidine (PCP): Effects of Modafinil and Relevance to Cognitive Deficits in Schizophrenia

  2010cites this paper
• Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.

  2010cites this paper
• The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities.

  2010cites this paper